Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D1.402 - Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection
D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management
D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases
D1.403 - Use of ketotifen as treatment for post viral infection cough in children
D1.404 - Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections
D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts
D1.406 - The microbiota of the urogenital canal related to papillomavirus infection
- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience
- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis
- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life
- D3.112 - Role of nasal cytology in patients with bronchial asthma
- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab
- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download